Anti-atherosclerotic effect of amlodipine, alone and in combination with atorvastatin, in APOE*3-Leiden/hCRP transgenic mice
Autor: | E.H. Offerman, Astrid Trion, Arnoud van der Laarse, Wouter Jukema, Moniek P.M. de Maat, Louis M. Havekes, Jef J. Emeis, Annemarie C.E. Maas, Hans M.G. Princen, Alexander J. Szalai |
---|---|
Přispěvatelé: | Urology, Cell biology |
Rok vydání: | 2006 |
Předmět: |
Genetically modified mouse
Apolipoprotein E medicine.medical_specialty Transgene Atorvastatin Hypercholesterolemia Apolipoprotein E3 chemistry.chemical_element Blood Pressure Mice Transgenic Pharmacology Calcium Lesion Mice Apolipoproteins E Internal medicine von Willebrand Factor medicine Animals Humans Pyrroles Amlodipine Serum Amyloid A Protein business.industry Antagonist Atherosclerosis Disease Models Animal C-Reactive Protein Cholesterol Endocrinology chemistry Heptanoic Acids Drug Therapy Combination Hydroxymethylglutaryl-CoA Reductase Inhibitors medicine.symptom Cardiology and Cardiovascular Medicine business medicine.drug |
Zdroj: | Journal of Cardiovascular Pharmacology, 47(1), 89-95. Lippincott Williams & Wilkins |
ISSN: | 1533-4023 0160-2446 |
Popis: | We investigated the pleiotropic effects of a calcium antagonist (amlodipine) on early atherosclerosis development in the presence and absence of an HMG-CoA-reductase inhibitor (atorvastatin) in apolipoprotein E*3-Leiden/human C-reactive protein (E3L/CRP) transgenic mice. Male E3L/CRP transgenic mice were fed a cholesterol-containing diet either with or without amlodipine and/or atorvastatin. After 31 weeks, atherosclerosis in the aortic root area was quantified. Treatment with amlodipine did not significantly lower blood pressure, but resulted in a 43% reduction (P < 0.03) of lesion area as compared with the untreated group. Treatment with atorvastatin resulted in an 80% reduction of lesion area as compared with the untreated group (P < 0.001). Combined treatment with amlodipine and atorvastatin decreased the lesion area by 93%, significantly more than either treatment alone (P < 0.008). Plasma C-reactive protein levels were mildly elevated, on average 10 +/- 6 mg/L, and did not differ between groups, neither on baseline nor during treatment. Treatment with amlodipine, independently of blood pressure lowering, reduced atherosclerosis development in E3L/CRP mice. Atorvastatin had a strong anti-atherosclerotic effect, whereas co-treatment with amlodipine enhanced this effect significantly. Plasma C-reactive protein levels were not affected by any of the three treatments. |
Databáze: | OpenAIRE |
Externí odkaz: |